Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia

References

• Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML-ETO, or CBFB-MYH 11 + acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746–2755
   PubMed Web of Science ®Google Scholar
• Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198–205.
   PubMed Web of Science ®Google Scholar
• Cloos J, Goermans BF, Hess CJ. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006;20:1217–1220.
   PubMed Web of Science ®Google Scholar
• Garg M, Moore H, Tobal K, et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 2003;123:49–59.
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Olsen LH, Hasle H, et al. WT1 gene expression:an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients--results from a single centre study. Br J Haematol 2004;125:590–600.
   PubMed Web of Science ®Google Scholar
• Valkova V, Polak J, Markova M, et al. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin Transplant 2013;27:E21–E29.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood. 2003;101:1698–1704.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia:a European LeukemiaNet study. J Clin Oncol 2009;27: 5195–5201.
   PubMed Web of Science ®Google Scholar
• Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009;82:61–68.
   PubMed Web of Science ®Google Scholar
• Zhao XS, Jin S, Zhu HH, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012;47:499–507.
   PubMed Web of Science ®Google Scholar
• Alonso-Dominguez JM, Tenorio M, Velasco D, et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet 2012;205:190–191.
   Google Scholar
• Zhao XS, Liu YR, Zhu HH, et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012;91:183–192.
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease , as detected by multiparametric flow cytometry, on outcome of myeloablative hemopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011;29:1190–1197.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Vidriales MB, Lopez-Berges C, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to post induction treatment stratification. Blood 2001;98:1746–1751.
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948–3952.
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, et al. determination of relapse risk based on assessment of minimal residual disease in unselected patients with acute myeloid leukemia. Blood 2004;104:3078–3085.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Hissaria P, et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. Am J Clin Pathol 2008;129:934–945.
   PubMed Web of Science ®Google Scholar
• Al-Mawali A, Gillis D, Lewis I. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B Clin Cytom 2009;76B:91–101.
   Web of Science ®Google Scholar
• Buccisano F, Maurillo L, del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332–341.
   PubMed Web of Science ®Google Scholar
• Maurillo L, Buccisano F, Del Principe MI, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944–4951.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Pullen DJ, Winick N, et al. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood lymphoblastic leukemia:implications for residual disease detection: a report from the Children's Oncology Group. Cytometry B Clin Cytom 2005;68:18–24.
   PubMed Web of Science ®Google Scholar
• Voskova D, Schoch C, Schnittger S, et al. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic and molecular genetic findings. Cytometry B Clin Cytom 2004;62:25–38.
   PubMed Web of Science ®Google Scholar
• Tomova A, Babusikova O. Shifts in expression of immunological cell markers in relapsed acute leukemia. Neoplasma 2006;53:500–506.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004;33:815–821.
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?J Clin Oncol. 2004;22:1696–1705.
   PubMed Web of Science ®Google Scholar
• Barrios M, Jimenez-Velasco A, Roman-Gomez J, et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003;88:801–810.
   PubMed Web of Science ®Google Scholar
• Bornhäuser M, Oelschlaegel U, Platzbecker U, et al. Monitoring of donor chimerism in sorted CD34 + peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009:94:1613–1617.
   PubMed Web of Science ®Google Scholar
• Lamba S, Abella E, Kukuruga D, et al. Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival. Leukemia 2004;18:1681–1686.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002;16:1423–1431.
   PubMed Web of Science ®Google Scholar
• Lion T, Watzinger F, Preuner S, et al. The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. Leukemia 2012;26:1821–1828.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important change. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–365.
   PubMed Web of Science ®Google Scholar
• Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012;26:123–135.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901–1928.
   PubMed Web of Science ®Google Scholar
• Kruger N, Bacher U, Bader P, et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: methods, acute leukemias, and myelodisplastic syndromes. Biol Blood Marrow Transplant 2010;16:1187–1211.
   PubMed Web of Science ®Google Scholar
• Kwon M, Martinez-Laperche C, Infante M, et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilm's tumor I expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012;1:1–8.
   Google Scholar
• Miyazaki T, Fujita H, Fujimaki K, et al. Clinical significance of minimal residual disease detected detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res 2012;36:998–1003.
   PubMed Web of Science ®Google Scholar
• Rossi G, Minervini MM, Carella AM, et al. Comparison between flow cytometry and WT1 RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets. Leuk Res 2012;36:401–406.
   PubMed Web of Science ®Google Scholar
• Rossi G, Nomdedeu JF, Minervini MM, et al. CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease. Eur J Haematol 2013;90:171–174.
   PubMed Web of Science ®Google Scholar
• Van de Loosdrecht AA, Alhan C, Bené MC, et al. Standardization of flow cytometry in myelodisplastic syndromes. Report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94:1124–1134.
   PubMed Web of Science ®Google Scholar